Background: Chronic kidney disease-mineral and bone disorder (CKD-MBD) is one of the most common complications in patients with CKD. As CKD-MBD is a systemic syndrome, prevention and management should be aimed at achieving better survival and less risk of cardiovascular events and fractures. Summary: Although target ranges for serum markers of mineral metabolism have been proposed in several global or local guidelines, these were mostly based on data from non-Asian patients. Additionally, there remain differences in medical and social systems as well as in economic status, even among Asian countries and areas. Key Message: Asian CKD patient data needs to be analyzed, published, and shared to establish optimal local strategies for CKD-MBD management.

1.
Fukagawa M, Hamada Y, Nakanishi S, Tanaka M: The kidney and bone metabolism: a nephrologist's view. J Bone Mineral Metab 2006;24:434-438.
2.
Lawson D, Kodicek E, et al: Identification of 1,25-dihyfroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 1971;230:228-230.
3.
Komaba H, Kakuta T, Fukagawa M: Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol 2011;5:797-809.
4.
Moe S, Drueke T, Cunningham J, et al: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-1953.
5.
Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M, Tominaga Y, Iseki K, Tsubakihara Y; Patient Registration Committee of the Japanese Society for Dialysis Therapy: Effects of serum levels of calcium, phosphorus, and intact PTH on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 2008;12:49-54.
6.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;76(suppl 113):S1-S130.
7.
London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Tranplant 2003;18:1731-1740.
8.
Fujii H, Joki N: Mineral metabolism and cardiovascular disease in CKD. Clin Exp Nephrol 2017;21(suppl 1):53-63.
9.
Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Cloning and characterizeation of FGF23 as a causative factor of tumor-induced ostomalacia. Proc Natl Acad Sci USA 2001;98:6500-6505.
10.
Komaba H, Fukagawa M: Phosphate - a poison for humans? Kidney Int 2016;90:753-763.
11.
Isakova T, Wahl P, Vargas GS, Gutierez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadebeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-1378.
12.
Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Tsubakihara Y, Isaka Y, Rakugi H: Combined use of vitamin D status and FGF23 for risk strafication of renal outcome. Clin J Am Soc Nephrol 2012;7:810-819.
13.
Gutierez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shaf A, Smith K, Lee H, Thadahani R, Jueppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysiss. N Engl J Med 2008;359:584-592.
14.
Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Oko A, Zhang X, Nissel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M: Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Fibrobast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014;25:349-360.
15.
Kuro-O M: The FGF23 and Klotho system beyond mineral metabolism. Clin Exp Nephrol 2017;21 (suppl 1):64-69.
16.
Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Guetierrez OM, Aguuillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Schilla J, Fischer M, Solomon EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadebeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
17.
Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, Pohl EE, Erben RG: FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med 2014;6:744-759.
18.
Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D: FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem 2014;289:9795-9810.
19.
Wolf M, Koch TA, Bergman DB: Effect of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Mineral Res 2013;29:1793-1803.
20.
Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, DiMarco GS, Brand M, Wolf M, Faul C: Fibroblast growth factor directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 2016;90:985-996.
21.
National Kidney Foundation: National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guideline for bone metabolism and diseases in chronic kidney disease. Am J Kidney Dis 2003;42(suppl 3):S1-S201.
22.
Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori M, Ashida A, Iseki K, Shigematsu T, Tsubakihara Y, Tomo T, Hirakata H, Akizawa T; for CKD-MBD Guideline Working Group, Japanese Society for Dialysis Therapy: Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder (CKD-MBD). Ther Aphr Dial 2013;17:247-288.
23.
Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, Shroff R, Thadhani RI, Tonelli MA, Kasiske BL, Wheeler DC, Leonard MB: Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2015;87:502-528.
24.
Danese MD, Belozeff V, Smimakis K, Rothman KJ: Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1423-1429.
25.
Goodkine DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003;14:3270-3277.
26.
Guideline Working GROUP, Japanese Society for Dialysis Therapy: Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008;12:514-525.
27.
Taniguchi M, Fukagawa M, Fujii N, Hamano T, Shoji T, Yokoyama K, Nakai S, Shigematsu T, Iseki K, Tsubakihara Y; Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy: Impact of mineral metabolism on mortality in hemodialysis patients: serum phosphate level should be controlled firstly and consistently. Ther Apher Dial 2013;17:221-228.
28.
Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S; and KRN1493 study group: Cinacalcet (KRN 1493) effectively decreases serum intact PTH level with favorable control of serum phohphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008;23:328-335.
29.
Yokoyama K, Katoh N, Kubo H, Murai S, Imamura N, Shoji R, Yamamoto H, Shigematsu T, Nakayama M, Takasu S, Kono T, Yoshida T, Hosoya T: Clinical signifye of the K/DOQI bone guideline in Japan. Am J Kidney Dis 2004;44:383-384.
30.
Tentori F, Wang M, Bieber B, Jacobson S, Andreucci V, Fukagawa M, Frimat L, Mendelssohn DA, Port F, Pisoni RL, Robinson BM: Recent changes in therapeutic approach and association with outcomes in the DOPPS study. Clin J Am Soc Nephrol 2015;10:98-109.
31.
Fukagawa M, Kido R, Komaba H, Onishi Y, Yamaguchi T, Hasegawa T, Kurita N, Akizawa T, Kurokawa K, Fukuhara S: Abnormal mineral metabolism associated with higher absolute mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis 2014;63:979-987.
32.
Kir S, Komaba H, Garcia AP, Economopoulos KP, Liu W, Lanske B, Hordin RA, Spiegelman BM: PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab 2016;23:315-323.
33.
Sugimoto R, Watanabe H, Ikegami K, Enoki Y, Imafuku T, Sakaguchi Y, Murata M, Nishida K, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T: The down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney Int 2017;91:658-670.
34.
Klahr S, Slatopolsky E: Toxicity of parathyroid hormone in uremia. Annu Rev Med 1986;37:71-78.
35.
Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M: Parathyroidectomy and survival among hemodialysis patients with secondary hyperparathyroidism: results from a nationwide registry in Japan. Kidney Int 2015;88:350-359.
36.
Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J-S, Shibuya K, Nishioka M, Hasegawa H, Kurosawa T, Fukagawa M: Cinacalcet effectively reduces parathyroid hormone secretion and gland hyperplasia regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010;5:2305-2314.
37.
Akizawa T, Kurita N, Mizobuchi M, Fukagawa M, Onishi Y, Yamaguchi T, Ellis AR, Fukuma S, Brookhart MA, Hasegawa T, Kurokawa K, Fukuhara S: PTH-dependence of the effectivess of cinacalcet inhemodialysis patients with secondary hyperparathyroidiam. Sci Rep 2016;6:19612.
38.
Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M: Cinacalcet treatment and FGF23 levels in dialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012;27:784-790.
39.
EVOLVE Trial Investigators; Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-2494.
40.
Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drueke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCL Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators: Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the Evaluation of Cinacalcet HCL Therapy to Lower Cardiovascular Events (EVOLVE) trial. Circulation 2015;132:27-39.
41.
Yokoyama K, Kurita N, Fukuma S, Akizawa T, Fukagawa M, Onishi Y, Kurokawa K, Fukuhara S: Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy. Nephrol Dial Transplant 2016, Epub ahead of print.
42.
Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Block G: A randomized double blind placebo-controlled trial of JTT-751 (ferric cytrate hydrate) on hyperphosphatemia in patients with non-dialysis dependent chronic kidney disease. Clin J Am Soc Nephrol 2014;9:543-552.
43.
Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T: Efficacy and safety of surroferric oxyhydroxide comared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphatemia: a randomized, open-label, multicenter, 12-week phase III study. Nephrology (Carlton) 2017;22:293-300.
44.
Fukagawa M, Yokoyama K, Shigematsu T, Akiba T, Fujii A, Kuramoto T, Odani M, Akizawa T: A phase 3, multicenter, randomized, double-blind, placebo-controlled, pararell-group study to evaluate the efficacy and safety of ethelcalcitide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant gfw408.
45.
Komaba H, Kakuta T, Suzuki H, Hida M, Suga T, Fukagawa M: Survival advantage for hemodialysis patients starting lanthanum carbonate for uncontrolled hyperphosphatemia. Nephrol Dial Transplant 2015;30:107-114.
46.
Hwang E, Choi B-S, Oh K-H, Kwon YJ, Kime C-H: Management of chronic kidney disease-mineral and bone disorder: Korean working group recommendations. Kidney Res Clin Prac 2015;34:4-12.
47.
Hasegawa T, Bragg-Gresham JL, Pisoni RL, Robinson BM, Fukuhara S, Akiba T, Saito A, Kurokawa K, Akizawa T: Changes in anemia management and hemoglobin levels following revision of bundling policy to incooporate recombineant hyman erythropoietin. Kidney Int 2011;79:340-346.
48.
Hamano T, Sakaguchi Y, Fujii N, Isaka Y: Clinical features of CKD-MBD in Japan: cohort studies and registry. Clin Exp Nephrol 2017;21(suppl 1):9-20.
49.
Hirukawa T, Kakuta T, Nakamura M, Fukagawa M: Mineral and bone disorders in kidney transplant recipets: reversible, irreversible and de novo abnormalities. Clin Exp Nephrol 2015;19:543-555.
50.
Goto S, Komaba H, Moriwaki K, Fujimori A, Shibuya K, Nishioka M, Kim J-I, Yoshiya M, Shin J-S, Hasegawa H, Taniguchi M, Fujii H, Nishi S, Fukagawa M: Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol 2011;6:1375-1384.
51.
Komaba H, Moriwaki K, Goto S, Yamada S, Taniguchi M, Kakuta T, Kamae I, Fukagawa M: Cost effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2012;60:262-271.
52.
JSDT registry data as of the end of 2014. http://www.jsdt.or.jp/overview_confirm.html (accessed December 26, 2016).
53.
Jin DC, Yun SR, Lee SW et al: Current characteristics of dialysis therapy in Korea: 2015 registry data focusing on elderly patients. Kidney Res Clin Pract. 2016;35: 204-211.
54.
Chinese National Renal Data System: The annual congress of Chinese Society of Nephrology 2016, Blood Purification Forum. Xiamen Shi, Fujian Sheng, China, May 5-7, 2016.
55.
2015 Annual Report on kidney disease in Taiwan. http://w3.nhri.org.tw/nhri_org/rl/lib/NewWeb/nhri/ebook/39000000425236.pdf (accessed December 26, 2016).
56.
Leung CB, Cheung WL, Li PK: Renal registry in Hong Kong - the first 20 years. Kidney Int Suppl (2011) 2015; 5:33-38.
57.
Singapore renal registry annual registry report 1999-2014. https://www.nrdo.gov.sg/docs/librariesprovider3/Publications-Kidney-Failure/report-1999-till-2014-interim.pdf?sfvrsn=0f (accessed December 26, 2016).
58.
22nd report of the Malaysian dialysis and transplant registry 2014. http://www.msn.org.my/Doc/PublicDoc_PB/Publication/mdtr22nd/content.pdf (accessed December 26, 2016).
59.
Thailand renal replacement therapy registration report 2014. http://www.nephrothai.org/images/10-11-2016/1.TRT-report-2014-_3-11-59_-final_.pdf (accessed December 26, 2016).
60.
JSDT registry data as of the end of 2015. http://www.jsdt.or.jp/overview_confirm.html.
61.
Kong X, Zhang L, Zhang L, et al: Mineral and bone disorder in Chinese dialysis patients: a multicenter study. BMC Nephrol 2012;13:116.
62.
Lin X, Yan Y, Ni Z, et al: Clinical outcome of twice-weekly hemodialysis patients in Shanghai. Blood Purif 2012;33: 66-72.
64.
Chinese Society of Nephrology. 2013: Guidance for diagnosis and treatment of mineral and bone disorder in chronic kidney disease.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.